中文

Alnylam (ALNY)

Biotech

Close on Nov 5, 2026 (from our latest article): $156.66

Market value
$21.0Bat the Nov 5 close
Revenue growth
+56%12 months to Sep 30, 2026 (10-Q)
FCF margin
16%12 months to Sep 30, 2026 (10-Q)
Net cash
$2.6Bat Sep 30, 2026
Worst fall since listing
−83.6%Oct 9, 2007 to Oct 3, 2011; back to that high in Jul 2013

About the company

Latest

  • Quarterly
    Alnylam Q3 2026: shares fall 25%; US demand adds less revenue than in Q2

The Long View

Alnylam spent years as a loss-making developer of RNAi drugs for rare diseases, until Amvuttra’s expansion into TTR heart disease, after a 2024 trial and a 2025 approval, drove growth and its first annual profit in 2025, helped by a $300M Roche milestone.

Self-funding

▲ better · ▼ worse · ⚠ watch, latest quarter · share count · cash

Updated Nov 5, 2026

Read the Long View →

Our View Opinion

Alnylam is now a profitable one-drug company: Amvuttra, its heart and nerve drug for transthyretin (TTR) amyloidosis, brings in nearly 80% of revenue, and the stock has fallen about 63% in a year as the heart launch has grown more slowly than promised; in October management said it isn't satisfied with demand.

Median value, end-2030
$370P10–P90 $250–$540
Chance of beating the hurdle
95%
Implied end-2030 multiple
5.1× 2031 salesP25–P75 4.2–6.1× · today 3.1×

Biggest risk: Our model's central downside case is a plateau, not a collapse, though more severe outcomes remain possible: Amvuttra settles as a second-line or add-on drug while cheap stabilizers keep first-line patients, and the company keeps growing profitably but slowly after 2027.

Nov 5, 2026 · our analysis, not investment advice

Read Our View →

More of our coverage that names Alnylam

Long-term fundamentals

Annual results for Alnylam, FY2009–FY2025, as reported in its 10-K filings.

Revenue and free cash flow

Revenue went from $101M in FY2009 to $3.7B in FY2025. Free cash flow was positive in 2 of the 17 years shown; FY2025: $465M. Each year's figures are in the table below. −$1B$0$1B$2B$3B$4B ’09 ’11 ’13 ’15 ’17 ’19 ’21 ’23 ’25

Revenue went from $101M in FY2009 to $3.7B in FY2025.

Free cash flow was positive in 2 of the 17 years shown; FY2025: $465M.

Margins

Operating margin was 14% in FY2025, vs −168% in FY2020. Each year's figures are in the table below. −1250%−1000%−750%−500%−250%0%250% ’10’17’19’21’23’25

Operating margin was 14% in FY2025, vs −168% in FY2020.

Diluted share count

The diluted share count rose 17% from FY2020 to FY2025, to 135M. Each year's figures are in the table below. 100M110M120M130M140M ’19’20’21’22’23’24’25

The diluted share count rose 17% from FY2020 to FY2025, to 135M.

Results and cash flow

Fiscal yearRevenueGross marginOperating marginNet incomeOperating cash flowCapital spendingFree cash flow
FY2025$3.7B—14%$314M$524M$59M$465M
FY2024$2.2B—−8%−$278M−$8M$34M−$43M
FY2023$1.8B—−15%−$440M$104M$62M$42M
FY2022$1.0B—−76%−$1.1B−$541M$72M−$613M
FY2021$844M—−84%−$853M−$642M$76M−$718M
FY2020$493M—−168%−$858M−$615M$70M−$685M
FY2019$220M—−427%−$886M−$278M$140M−$419M
FY2018$75M—−1088%−$761M−$563M$127M−$690M
FY2017$90M—−556%−$491M−$383M$104M−$487M
FY2016$47M—−900%−$410M−$308M$65M−$372M
FY2015———−$290M−$189M$13M−$202M
FY2014———−$360M−$166M$9M−$175M
FY2013———−$89M−$69M$4M−$73M
FY2012———−$106M−$116M$8M−$124M
FY2011———−$58M−$87M$1M−$88M
FY2010$100M—−44%−$44M−$84M$5M−$89M
FY2009$101M—−48%−$48M−$72M$5M−$77M

Shares, cash, debt and payouts

Fiscal yearDiluted sharesCash and investmentsDebtStock-based payDividends paidBuybacks
FY2025135M$2.9B$1.0B$348M——
FY2024128M$2.7B$1.0B$272M——
FY2023125M$2.4B$1.0B$222M——
FY2022122M$2.2B$1.0B$231M——
FY2021118M$2.4B$676M$166M——
FY2020115M$1.8B$191M$140M——
FY2019109M$1.5B$0$175M——
FY2018—$1.1B$30M$158M——
FY2017—$1.7B$30M$93M——
FY2016—$943M$150M$76M——
FY2015—$1.3B—$46M——
FY2014—$882M—$33M——
FY2013—$350M—$21M——
FY2012—$226M—$12M——
FY2011—$146M—$17M——
FY2010—$233M—$19M——
FY2009—$281M—$20M——

Source: company 10-K filings via SEC EDGAR (XBRL data); fiscal years. Data fetched Oct 30, 2026. Free cash flow is operating cash flow minus capital spending (our calculation; the company's own definition may differ). Margins are a share of revenue. "—" means the figure is not in the 10-K data.

Returns by year

YearALNYS&P 500
2019+58.0%+31.5%
2020+12.8%+18.4%
2021+30.5%+28.7%
2022+40.1%−18.1%
2023−19.5%+26.3%
2024+22.9%+25.0%
2025+69.0%+17.9%
2026 to date−62.8%+5.9%

Total return, with dividends reinvested: each year from the last close of the year before to the last close of the year; 2026 to date runs to the Nov 19, 2026 close. The S&P 500 is its total return index. Our calculation from Yahoo Finance daily closes and adjusted closes; not investment advice.

Other companies we cover in Biotech

Show all 17

Questions about Alnylam

How does Alnylam make money?
Alnylam sells RNA interference (RNAi) medicines, which reduce production of selected disease-causing proteins. In 2025 Amvuttra, for transthyretin (TTR) amyloidosis, was 62% of its $3.71B revenue. The rest came from older drugs (Onpattro, Givlaari and Oxlumo), collaboration payments (mainly Roche, including a one-time $300M milestone) and royalties (mainly Novartis's Leqvio). More in the Long View →
What drives Alnylam's growth?
Amvuttra's expansion into TTR amyloidosis affecting the heart, following US approval in 2025, drove growth. Alnylam reported its first annual GAAP profit in 2025, helped by a one-time $300M Roche milestone. More in the Long View →
How dependent is Alnylam on Amvuttra?
Amvuttra accounted for 62% of Alnylam's total revenue in 2025. Alnylam pays Sanofi tiered royalties of 15–30% on Amvuttra sales. More in the Long View →
What are the main risks to Alnylam's business?
Alnylam identifies insurer reimbursement as a sales risk. Amvuttra is paid for mainly under Medicare Part B, a meaningful portion of its US units is bought under the 340B discount programme, and certain Medicare Advantage plans now require patients to try another drug first. Its distributor concentration creates credit and distribution exposure, and it shares Amvuttra's economics with Sanofi and Blackstone. More in the Long View →
What could follow Amvuttra?
Alnylam is developing nucresiran, an investigational successor for TTR amyloidosis that carries no Sanofi royalty. It still requires successful clinical development and regulatory approval. More in the Long View →
What's coming up for Alnylam's pipeline in the next 12 months?
Alnylam expects Phase 2 ALN-6400 data in hereditary hemorrhagic telangiectasia and Phase 1 ALN-2232 data in obesity and weight management with its fourth quarter and full year 2026 earnings call in February 2027. It plans a pivotal brezosiran study in 2027, pending regulatory alignment. Alnylam says Regeneron's cemdisiran has a PDUFA target action date in November 2026; if approved, Alnylam is eligible for royalties. As of Nov 5, 2026 More in the Long View →

Disclosure: one or more of our editors own shares of Alnylam (ALNY) as a long-term investment.